No difference in efficacy between Xeomin® and Botox® in the treatment of cervical dystonia – a detailed subgroup analysis

Introduction: Treatment of cervical dystonia (CD) with the highly purified Botulinum neurotoxin type A (BTX-A) free of complexing proteins (Xeomin) is mainly based on the largest controlled study of BTX-A ever performed (Benecke et al. 2005) demonstrating that Xeomin is non-inferior to Botox and that in average the efficacy of one Xeomin unit is equivalent to one Botox unit. To support this dose ratio, we re-analysed the data of this study whether various subgroups of patients revealed a different response to Xeomin or Botox. Results: The separate analysis of the TWSTRS – Severity score with regard to subgroups…